– Experts demand more understanding and better support
– Astellas Pharma Europe Ltd. today published the results of a European survey of 200 nephrologists and 203 patients with chronic kidney disease anemia. The study reveals the stress on the physical and mental health of patients caused by the disease. Over half of the patients surveyed reported that their illness determines their everyday life (57%), with 41% of the patients expressing feelings of social isolation due to their condition. Experts believe that a deeper understanding of the patient burden of chronic kidney failure anemia is needed among healthcare professionals, along with a greater focus on patient quality of life in daily routine.
Anemia is a common complication of chronic kidney disease, affecting one in five people.1 It leads to symptoms such as lack of energy, fatigue, and shortness of breath2 that can affect patients both at work and at home. The results of the survey show that the symptoms influenced the everyday life of 83% of the surveyed patients, which led to absenteeism of more than eight days per month on average. For almost half of the patients surveyed (44%), their condition meant that they had to stop working for an indefinite period of time. In addition to the work, more than two-thirds of the patients surveyed (67%) reported that they needed help around the house, which further illustrates the far-reaching effects of the anemia caused by kidney failure on the quality of life of the patients. The survey infographic provides additional insight from patients and nephrologists about the diagnosis, management, and the stress of living with anemia due to kidney disease.
Astellas appointed a team of five external experts to provide their views on the survey results. The team of experts included two senior nephrology professors (United Kingdom and Spain), a specialist renal nurse (United Kingdom), the president of a European association of renal nurses and the president of a national patient group (Spain). A detailed overview of the survey results and the assessments of the expert team can be found in the comprehensive survey report. The following key observations and actions were identified by the team of experts for future condition management:
“There is a clear need for a better understanding of what aspects of a patient’s condition affect their quality of life.” Jennifer Ann Williams, Specialized Kidney Nurse, Abertawe Bro Morgannwg University Health Board, UK.
“It’s no surprise that patients experience social isolation because of their condition. They’re tired and don’t want to go out or meet friends. They just don’t want to do anything.” Kidney Diseases (ALCER), Spain.
“It is important to consider the individual characteristics of the patient when it comes to the effects of anemia on everyday life.” Professor José Portolés Pérez, nephrologist at the University Hospital Puerta de Hierro de Majadahonda, Spain.
Together, these findings from patients, nephrologists and experts show that nephrologists need a better understanding of the psychological and physical stress on patients caused by anemia in renal insufficiency and that the patient’s quality of life needs to be given greater consideration in the treatment of the disease.
“At Astellas, tomorrow’s change is the ethos that guides everything we do. We recognize that addressing unmet needs is often best achieved in collaboration with others. This survey is just one of the initiatives we are engaged in with patient groups and professional organizations work to provide value to people with chronic kidney disease, their loved ones and the healthcare professionals who treat their condition. ” Gino Ciotti, Medical Director for Medical Affairs, Nephrology, Astellas.
To learn more about chronic kidney disease anemia, visit us at: www.astellas.com/eu/therapy-areas/nephrology
About Beyond CKD: The Hidden Truth Behind Anemia
Between January and February 2020, research firm Research Partnership conducted a survey on behalf of Astellas Europe Limited to investigate the assessment of patients and nephrologists regarding chronic kidney disease and the anemia it causes.
The participants were recruited through online committees and were suitable if:
– a patient has been diagnosed with anemia due to renal insufficiency.
– a nephrologist who has been practicing for at least two years and who has treated at least eight patients with anemia due to renal insufficiency from the third stage. The participants took part in a 25-minute quantitative online survey.
You can find out more about the survey at www.astellas.com/eu/media-centre/media-resources.
About chronic kidney disease and anemia
Renal insufficiency is characterized by a progressive loss of kidney function, which is caused by damage to the kidneys as a result of symptoms such as high blood pressure, diabetes or immune-regulated inflammatory conditions.3 One in ten people worldwide lives with chronic kidney disease.4 In Europe, one in eight people lives with it chronic kidney disease.4 According to data from the United Kingdom, every fifth patient with chronic kidney disease has anemia. In people with the most severe kidney disease (stage 5 kidney failure), this rate increases to every second patient.1 Globally, it is forecast that chronic kidney disease will be the fifth leading cause of premature death by 2040.5 It is a critical health problem worldwide, the one brings great and growing unmet medical needs with it.
Anemia is a common complication of chronic kidney failure, 6 resulting from the failure of the kidneys to produce erythropoietin, decreased oxygen uptake, and increased hepzidine and iron deficiency due to chronic inflammation. This is related to significant morbidity and mortality in both dialysis and non-dialysis patients, increasing in both incidence and severity as kidney disease progresses.7 Anemia in kidney disease increases the risk of adverse effects on the cardiovascular system, deteriorating kidney outcome and can have a negative impact on patients’ quality of life.8-10
Astellas Pharma Inc. is a pharmaceutical company operating in over 70 countries worldwide. We support the focus-area approach, which aims to identify opportunities for the continuous development of new drugs to treat diseases with high unmet unmet medical needs by focusing on biology and modality. We also look beyond our fundamental Rx focus to create Rx + ® solutions for the healthcare sector that combine our specialist knowledge and experience with cutting-edge technology in the various fields of activity of external partners. With these accomplishments, Astellas is at the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/eu.
This press release contains statements relating to current plans, estimates, strategies, and beliefs and other statements that are not historical facts but forward-looking statements about Astellas’ future performance. These statements are based on the current assessments and beliefs of management in view of the information currently available to it. They involve known and unknown risks and uncertainties. Various factors could cause actual results to differ materially from the forward-looking statements. These factors include, but are not limited to: (i) changes in the general economic situation and laws and regulations pertaining to the pharmaceutical markets, (ii) currency fluctuations, (iii) delayed launches of new products, (iv) poor marketing by Astellas of existing and new products, (v) Astellas ‘inability to continue effective research and development of products that are accepted by customers in highly competitive markets, and (vi) third party infringement of Astellas’ intellectual property rights.
Any drug information (including products currently under development) featured in this press release is not intended to be used as advertising or as medical advice.
1 Dmitrieva O, de Lusignan S, Macdougall IC, et al. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrol 2013;14:24.
2 National Kidney Foundation. Anemia and Chronic Kidney Disease. Erhältlich unter: https://www.kidney.org/atoz/content/what_anemia_ckd. [Letzter Aufruf: Juni 2020]
3 Ojo A. Addressing the Global Burden of Chronic Kidney Disease Through Clinical and Translational Research. Trans Am Clin Climatol Assoc 2014;125:229-246.
4 International Society of Nephrology. Chronic Kidney Disease. Global Kidney Health Atlas 2017. Erhältlich unter: www.theisn.org/global-atlas (http://www.theisn.org/global-atlas) [Letzter Aufruf: Juni 2020].
5 Institute for Health Metrics and Evaluation (IHME). Findings from the Global Burden of Disease Study 2017. Seattle, WA: IHME, 2018. Erhältlich unter: http://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017_Booklet.pdf [Letzter Aufruf:: Juni 2020].
6 McClellan W, Aronoff SL, Kline Bolton W, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-1510.
7 Stauffer ME und Fan T. Prevalence of Anemia in Chronic Kidney Disease in the United States. PLoS One 2014;9:e84943.
8 Mohanram A, Zhang Z, Shahinfar S, et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004;66:1131-1138.
9 Weiner DE, Tighiouart H, Stark PC, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004;44:198-206.
10 Eriksson D, Goldsmith D, Teitsson S, et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol 2016;17:97.
Tel.: +44 7771 803076
Original content by: Astellas Pharma Europe Limited, transmitted by news aktuell
Original message: https://www.presseportal.de/pm/61801/4717685